NCT06096779 2026-03-06
Kirros
Genentech, Inc.
Phase 2 Recruiting
Clinical Trials
18 trialsNCT07447050 2026-03-03
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
Phase 2 Recruiting
NCT04134559 2026-02-24
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07223307 2026-02-09
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Stanford University
Phase 2 Recruiting
NCT06679985 2026-02-05
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Recruiting
NCT07246668 2025-11-24
A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
Yonsei University
Phase 2 Recruiting
NCT07145801 2025-10-07
TARE
Thomas Jefferson University
Phase 2 Recruiting
NCT04912765 2025-09-23
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
National Cancer Centre, Singapore
Phase 2 Recruiting
NCT06015022 2025-09-05
CATCH-B
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT07105748 2025-08-17
TASK-05
Fudan University
Phase 2 Recruiting
NCT05451043 2025-06-26
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT06580002 2025-06-26
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
University of California, Irvine
Phase 2 Recruiting
NCT05992220 2025-02-21
ALERT-HCC
Asan Medical Center
Phase 2 Recruiting
NCT06114082 2025-01-07
IDADOX
Seoul National University Hospital
Phase 2 Recruiting
NCT05185739 2024-12-06
PRIMER-1
University College, London
Phase 2 Recruiting
NCT05412589 2024-07-31
mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT06482801 2024-07-01
Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT04988945 2023-09-06
TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
The University of Hong Kong
Phase 2 Recruiting